文献速递造血干细胞移植与细胞治疗白血病

成人EB病毒相关噬血细胞性淋巴组织细胞增多症患者是否应行移植:是或否?

Transplantation in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: yes or no?
PubMed 文献 · Blood · 2024-01-01

研究纳入356例成人EB病毒相关噬血细胞性淋巴组织细胞增多症(EBV-HLH)患者,88例在医学建议下接受造血干细胞移植(HSCT),4例接受挽救性HSCT。HSCT组5年总生存率为48.7%,未移植组为16.2%(P < .001)。HSCT显著改善成人EBV-HLH生存;初始治疗后达部分缓解者推荐HSCT,达完全缓解者可采取观察等待策略但存在未达第二次完全缓解的风险。

要点

  • HSCT组5年OS为48.7%,未移植组为16.2%(P < .001)。
  • 首次完全缓解(CR1)与首次部分缓解(PR1)时移植者OS无差异,CR1与CR2移植者亦无差异。
  • 初始治疗后达PR者推荐HSCT;达CR者可观察等待,但存在未达CR2的风险。

核心结论

  • HSCT显著改善成人EBV-HLH患者的生存。
  • 初始治疗后达部分缓解(PR)的患者推荐行HSCT。
  • 初始治疗后达完全缓解(CR)的患者可采取观察等待策略,但存在未能达到第二次完全缓解(CR2)的风险。

研究设计与样本

  • 研究纳入356例成人EBV-HLH患者,其中88例在医学建议下接受HSCT,4例接受挽救性HSCT。

主要发现

  • HSCT组5年总生存(OS)率为48.7%,未移植组为16.2%(P < .001)。
  • 在CR1与PR1时接受移植的患者之间OS无差异,在CR1与CR2时接受移植的患者之间亦无差异。
  • 在PR2时接受移植的患者生存较差。
  • CR1患者达到CR2的比例显著高于PR1患者(P = .014)。
  • 较高的可溶性CD25水平、HSCT后较高的血浆EBV-DNA载量、较差的缓解状态、较严重的急性移植物抗宿主病(GVHD)以及缺乏局限性慢性GVHD与较差预后相关(P < .05)。

临床怎么用

  • 对于初始治疗后达到PR的成人EBV-HLH患者,推荐行HSCT。
  • 对于初始治疗后达到CR的患者,可采取观察等待策略,但存在未能达到CR2的风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by aberrant immunological activity with a dismal prognosis. Epstein-Barr virus (EBV)-associated HLH (EBV-HLH) is the most common type among adults. Patients with EBV infection to B cells could benefit from rituximab, whereas lethal outcomes may occur in patients with EBV infection to T cells, nature killer cells, or multilineages. The necessity of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with EBV-HLH remains controversial. A total of 356 adult patients with EBV-HLH entered this study. Eighty-eight received HSCT under medical recommendation. Four received salvage HSCT. The 5-year overall survival (OS) rate for patients who underwent HSCT was 48.7% (vs 16.2% in patients who did not undergo transplantation; P < .001). There was no difference in OS between patients who received transplantation at first complete response (CR1) and those at first partial response (PR1) nor between patients at CR1 and CR2. Patients who received transplantation at PR2 had inferior survival. The rate of reaching CR2 was significantly higher in patients with CR1 than PR1 (P = .014). Higher soluble CD25 levels, higher EBV-DNA loads in plasma after HSCT, poorer remission status, more advanced acute graft-versus-host disease (GVHD), and the absence of localized chronic GVHD were associated with inferior prognosis (P < .05). HSCT improved the survival of adult EBV-HLH significantly. For patients who achieved PR after initial treatment, HSCT was recommended. A wait-and-see strategy could be adopted for patients who achieved CR after initial treatment but with the risk of failing to achieve CR2.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Yao S, He L, Suolitiken D, et al. Transplantation in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: yes or no? Blood. 2024. PMID: 39093986. doi:10.1182/blood.2023023287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。